Eton Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
Eton Pharmaceuticals, Inc. (ETON) reported Increase (Decrease) in Accrued Liabilities of $704.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $2.24M, a 1200.00% increase year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.53M.
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $426.00K, a 79.15% decline year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.79M, a 211.15% increase year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $1.01M, a 31.87% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $1.48M, a 40.09% decline from fiscal 2023.
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $2.48M, a 70.95% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $1.45M, a 1149.14% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 5 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 8 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $704.00K 10-Q · filed 2026-08-13 | $1.13M derived: sum of 3 quarters · filed 2026-08-13 | $2.92M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2026-03-31 | -$1.53M 10-Q · filed 2026-05-14 | -$1.11M derived: sum of 2 quarters · filed 2026-05-14 | $680.00K derived: sum of 3 quarters · filed 2026-05-14 | $852.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-12-31 | $426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.21M derived: sum of 2 quarters · filed 2026-03-19 | $2.38M derived: sum of 3 quarters · filed 2026-08-13 | $1.01M 10-K · filed 2026-03-19 | ||||||
| 2025-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.96M derived: sum of 2 quarters · filed 2026-08-13 | $585.00K 10-Q · filed 2025-11-06 | $2.63M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-06-30 | $172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.20M 10-Q · filed 2026-08-13 | $842.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.42M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-03-31 | -$1.37M 10-Q · filed 2026-05-14 | $670.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.24M derived: sum of 3 quarters · filed 2026-05-14 | $1.75M derived: sum of 4 quarters · filed 2026-05-14 | ||||||
| 2024-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.62M derived: sum of 2 quarters · filed 2026-03-19 | $3.12M derived: sum of 3 quarters · filed 2026-03-19 | $1.48M 10-K · filed 2026-03-19 | ||||||
| 2024-09-30 | $574.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.08M derived: sum of 2 quarters · filed 2025-11-06 | -$559.00K 10-Q · filed 2025-11-06 | $815.00K derived: sum of 4 quarters · filed 2026-03-19 | ||||||
| 2024-06-30 | $506.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.13M 10-Q · filed 2025-08-07 | $2.38M 10-Q · filed 2024-08-08 | $241.00K derived: sum of 3 quarters · filed 2026-03-19 | -$701.00K derived: sum of 4 quarters · filed 2026-03-19 | |||||
| 2024-03-31 | -$1.64M 10-Q · filed 2025-05-13 | -$1.02M 10-Q · filed 2024-05-09 | -$265.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.21M derived: sum of 3 quarters · filed 2026-03-19 | -$401.00K derived: sum of 4 quarters · filed 2026-03-19 | |||||
| 2023-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $432.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.24M derived: sum of 3 quarters · filed 2026-03-19 | $2.48M 10-K · filed 2026-03-19 | $5.29M 10-K · filed 2024-03-14 | |||||
| 2023-09-30 | -$942.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$136.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.10M 10-Q · filed 2024-11-12 | $3.44M 10-Q · filed 2023-11-09 | $1.04M derived: sum of 4 quarters · filed 2025-03-18 | |||||
| 2023-06-30 | $806.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.04M 10-Q · filed 2024-08-08 | $1.98M derived: sum of 3 quarters · filed 2025-03-18 | $2.73M derived: sum of 4 quarters · filed 2025-03-18 | ||||||
| 2023-03-31 | $1.24M 10-Q · filed 2024-05-09 | $1.18M derived: sum of 2 quarters · filed 2025-03-18 | $1.93M derived: sum of 3 quarters · filed 2025-03-18 | $2.72M derived: sum of 4 quarters · filed 2025-03-18 | ||||||
| 2022-12-31 | -$64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $686.00K derived: sum of 2 quarters · filed 2025-03-18 | $1.48M derived: sum of 3 quarters · filed 2025-03-18 | $1.45M 10-K · filed 2025-03-18 | $2.22M 10-K · filed 2023-03-16 | |||||
| 2022-09-30 | $750.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.54M derived: sum of 2 quarters · filed 2023-11-09 | $1.51M 10-Q · filed 2023-11-09 | $1.63M derived: sum of 4 quarters · filed 2024-03-14 | ||||||
| 2022-06-30 | $793.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $763.00K 10-Q · filed 2023-08-10 | $883.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.25M derived: sum of 4 quarters · filed 2024-03-14 | ||||||
| 2022-03-31 | -$30.00K 10-Q · filed 2023-05-11 | $90.00K derived: sum of 2 quarters · filed 2024-03-14 | $458.00K derived: sum of 3 quarters · filed 2024-03-14 | $564.00K derived: sum of 4 quarters · filed 2024-03-14 | ||||||
| 2021-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $488.00K derived: sum of 2 quarters · filed 2024-03-14 | $594.00K derived: sum of 3 quarters · filed 2024-03-14 | $116.00K 10-K · filed 2024-03-14 | ||||||
| 2021-09-30 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $474.00K derived: sum of 2 quarters · filed 2022-11-10 | -$4.00K 10-Q · filed 2022-11-10 | -$234.00K 10-Q · filed 2021-11-16 | $311.00K derived: sum of 4 quarters · filed 2023-03-16 | |||||
| 2021-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$372.00K 10-Q · filed 2022-08-11 | -$57.00K derived: sum of 3 quarters · filed 2023-03-16 | $111.00K derived: sum of 4 quarters · filed 2023-03-16 | ||||||
| 2021-03-31 | -$478.00K 10-Q · filed 2022-05-12 | -$163.00K derived: sum of 2 quarters · filed 2023-03-16 | $5.00K derived: sum of 3 quarters · filed 2023-03-16 | -$242.00K derived: sum of 4 quarters · filed 2023-03-16 | ||||||
| 2020-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $483.00K derived: sum of 2 quarters · filed 2023-03-16 | $236.00K derived: sum of 3 quarters · filed 2023-03-16 | -$300.00K 10-K · filed 2023-03-16 | ||||||
| 2020-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | -$79.00K derived: sum of 2 quarters · filed 2021-11-16 | -$615.00K 10-Q · filed 2021-11-16 | $182.00K derived: sum of 4 quarters · filed 2022-03-16 | ||||||
| 2020-06-30 | -$247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$783.00K 10-Q · filed 2021-08-16 | $14.00K derived: sum of 3 quarters · filed 2022-03-16 | -$38.00K derived: sum of 4 quarters · filed 2022-03-16 | ||||||
| 2020-03-31 | -$536.00K 10-Q · filed 2021-05-13 | $261.00K derived: sum of 2 quarters · filed 2022-03-16 | $209.00K derived: sum of 3 quarters · filed 2022-03-16 | $304.00K derived: sum of 4 quarters · filed 2022-03-16 | ||||||
| 2019-12-31 | $797.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $745.00K derived: sum of 2 quarters · filed 2022-03-16 | $840.00K derived: sum of 3 quarters · filed 2022-03-16 | $534.00K 10-K · filed 2022-03-16 | ||||||
| 2019-09-30 | -$52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $43.00K derived: sum of 2 quarters · filed 2020-11-12 | -$263.00K 10-Q · filed 2020-11-12 | -$64.00K derived: sum of 4 quarters · filed 2021-03-16 | ||||||
| 2019-06-30 | $95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$211.00K 10-Q · filed 2020-08-12 | -$12.00K derived: sum of 3 quarters · filed 2021-03-16 | $126.00K derived: sum of 4 quarters · filed 2021-03-16 | ||||||
| 2019-03-31 | -$306.00K 10-Q · filed 2020-05-14 | -$107.00K derived: sum of 2 quarters · filed 2021-03-16 | $31.00K derived: sum of 3 quarters · filed 2021-03-16 | $151.00K derived: sum of 4 quarters · filed 2021-03-16 | ||||||
| 2018-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $337.00K derived: sum of 2 quarters · filed 2021-03-16 | $457.00K derived: sum of 3 quarters · filed 2021-03-16 | $349.00K 10-K · filed 2021-03-16 | ||||||
| 2018-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $258.00K derived: sum of 2 quarters · filed 2019-11-14 | $150.00K 10-Q · filed 2019-11-14 | |||||||
| 2018-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $12.00K 10-Q · filed 2019-08-06 | ||||||||
| 2018-03-31 | -$108.00K 10-Q · filed 2019-05-07 | |||||||||
| 2017-12-31 | $254.00K 10-K · filed 2020-03-05 | |||||||||
| 2017-09-30 | $113.00K 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |